• Home
    • StockRanks™
    • Platform
        • Research & Discuss
        • Editorial & Community
        • Learn & Improve
        • Webinars & Masterclasses
        • Stockopedia Academy
    • Reviews
    • Pricing
    Get startedLog in
    SectorsHealthcareBiotechnology & Medical ResearchLiminatus Pharma
    Picture of Liminatus Pharma logo

    LIMN — Liminatus Pharma News Story

    $2.940.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    • Market Cap
      $3.95m
    • Enterprise Value
      $2.37m
    • Revenue
    • Quality
    • Value
    • Momentum
    • StockRank™
    • StockReport™
    • Accounts
      • Balance sheet
      • Income statement
      • Cashflow statement
      • Dividend summary
    • News
    • LIMN Dividends
    StockReport™
    Balance sheet
    Income statement
    Cashflow
    News
    LIMN Dividends
    All News

    NASDAQ RESUMED AT 01:13 PM

    Picture of Liminatus Pharma logoLiminatus Pharma
    04/02/2026 18:13
    NASDAQ RESUMED  LIMN.O  AT 01:13 PM
    

    Recent news on Liminatus Pharma

    See all news
    • NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM

      21/08/2026 08:58
    • NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM

      21/08/2026 24:50
    • Brief: Liminatus Pharma Announces Reverse Stock Split Of Its Common Stock

      18/08/2026 21:09
    • Brief: Liminatus Pharma Announces Planned Phase 1 Clinical Trial Of Iba101, A Next-Generation Cd47 Blocking Antibody

      17/03/2026 12:09
    • Brief: Liminatus Pharma Enters Settlement Agreement With Clear Street LLC

      09/02/2026 20:06

    Company

    • About us
    • Careers
    • Product Guide

    Our Coverage

    • Countries
    • Sectors
    • Ratios

    Top Stocks

    • UK Stocks
    • Australian Stocks
    • US Stocks

    Legals

    • Privacy Policy
    • Terms & Conditions
    • Disclaimer & FSG
    • Cookies
    Trustpilot
    Select a country/region:


    © Stockopedia 2026, Refinitiv, Share Data Services.

    *Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.

    This site cannot substitute for professional investment advice or independent factual verification. To use Stockopedia, you must accept our Terms of use, Privacy and Disclaimer & FSG. All services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.